Experimental cancer drug TAK-500 tested in 61 patients – trial halted early

NCT ID NCT05070247

Terminated Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jan 24, 2026 · Last updated Jun 22, 2026 · Updated 19 times

Summary

This study tested a new drug called TAK-500, given alone or with another immunotherapy (pembrolizumab), in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The goal was to check safety and see if the drug could shrink tumors. The trial was terminated early, so results are limited, but researchers were looking for side effects and signs of tumor response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
New York University

New York, New York, 10016-4744, United States
Northwestern

Chicago, Illinois, 60611, United States
START South Texas Accelerated Research Therapeutics

San Antonio, Texas, 78229, United States
Sarah Cannon Cancer Institute

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute

Denver, Colorado, 80218, United States
Sylvester Comprehensive Cancer Center

Miami, Florida, 33136, United States
Univeristy of Alabama at Birmingham

Birmingham, Alabama, 35294, United States
University of California San Diego

La Jolla, California, 92093, United States
University of Colorado - Anschutz Medical Campus - PPDS

Aurora, Colorado, 80045, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

TAK-500 (a drug that activates the immune system) and pembrolizumab (an immunotherapy)

What this could lead to

If it works, this could point toward a new treatment option for several advanced cancers that have stopped responding to standard therapies.

What could go wrong

This is an early-phase trial (Phase 1/2) that was terminated, so results are limited. The drug may cause significant side effects, and its effectiveness is not yet proven.

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm clear cell renal carcinoma esophageal adenocarcinoma esophageal cancer Esophageal Neoplasms gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal adenocarcinoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma hepatocellular carcinoma kidney cancer Liver Neoplasms malignant pancreatic neoplasm mesothelioma nasopharyngeal carcinoma nasopharyngeal carcinoma, susceptibility to, 1 nasopharyngeal neoplasm non-small cell lung carcinoma pancreatic adenocarcinoma pancreatic neoplasm pediatric hepatocellular carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER ESOPHAGEAL CANCER GASTRIC CANCER HEPATOCELLULAR CANCER HEPATOCELLULAR CANCER KIDNEY CANCER MESOTHELIOMA NASOPHARYNGEAL CANCER NON-SMALL CELL LUNG CANCER (NSCLC), NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC), NON-SQUAMOUS PANCREATIC CANCER SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN)